` ROVI (Laboratorios Farmaceuticos ROVI SA) vs DAX Index Comparison - Alpha Spread

ROVI
vs
DAX Index

Over the past 12 months, ROVI has underperformed DAX Index, delivering a return of -42% compared to the DAX Index's 13% growth.

Stocks Performance
ROVI vs DAX Index

Loading

Performance Gap
ROVI vs DAX Index

Loading
ROVI
DAX Index
Difference

Performance By Year
ROVI vs DAX Index

Loading
ROVI
DAX Index
Add Stock

Competitors Performance
Laboratorios Farmaceuticos ROVI SA vs Peers

DAX Index
ROVI
LLY
JNJ
NOVO B
ROG
Add Stock

Laboratorios Farmaceuticos ROVI SA
Glance View

Economic Moat
Narrow
Market Cap
2.5B EUR
Industry
Pharmaceuticals

Laboratorios Farmacéuticos ROVI SA has carved a niche for itself in the pharmaceutical industry through its focus on researching, developing, manufacturing, and marketing a broad range of small molecule drugs and specialized products. Founded in Spain, ROVI has channeled its efforts towards creating innovative solutions in the healthcare sector, with heparin-based products emerging as a cornerstone of its portfolio. The company's operational model is built on vertical integration, allowing it to control the entire lifecycle of its offerings, from production to commercialization. This approach not only ensures quality and compliance with stringent regulatory standards but also enables ROVI to adapt nimbly to market demands and leverage its proprietary science to secure a competitive edge. The revenue streams of ROVI are diversified across its proprietary products, contract manufacturing services, and its portfolio of licensed products. A significant portion of revenue stems from its commitment to injectable drug products like Bemiparin, a low molecular weight heparin, which has found a foothold in various international markets. Moreover, ROVI capitalizes on partnerships and alliances with major pharmaceutical giants, augmenting its contract manufacturing capabilities and tapping into more extensive distribution networks. Not resting on its laurels, ROVI invests heavily in research and development to fortify its pipeline with innovative formulations, thus ensuring sustained growth and a resilient positioning in the global pharmaceutical landscape. This blend of strategic partnerships, internal innovation, and market-responsive production underscores ROVI's business model and revenue generation prowess.

ROVI Intrinsic Value
81.16 EUR
Undervaluation 40%
Intrinsic Value
Price
Back to Top